We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 62.00
High: 62.00
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Aug 2017 15:45

RNS Number : 8288N
Tissue Regenix Group PLC
11 August 2017
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

TISSUE REGENIX GROUP PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Share Placing

X

3. Full name of person(s) subject to thenotification obligation: iii

NFU Mutual Insurance Society Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

10th August 2017

6. Date on which issuer notified:

11th August 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares

26,264,000

26,264,000

26,264,000

26,264,000

2.262%

GB00B5SGVL29

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

26,264,000

2.262%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

NFU Mutual Insurance Society (General Fund) 2.262% (Direct)

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Adam Inman

15. Contact telephone number:

01789 202693

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUAOSRBVAWAAR
Date   Source Headline
18th Jul 20222:42 pmRNSHolding(s) in Company
18th Jul 20221:33 pmRNSHolding(s) in Company
15th Jul 20225:29 pmRNSHolding(s) in Company
27th Jun 20226:04 pmRNSHolding(s) in Company
27th Jun 202212:58 pmRNSHolding(s) in Company
16th Jun 20221:27 pmRNSExercise of Options and Total Voting Rights
28th Apr 20227:00 amRNSOrthoPure®XT clinical results presentation
26th Apr 20224:19 pmRNSResult of AGM
20th Apr 20224:26 pmRNSDirector/PDMR Shareholding
19th Apr 20227:15 amEQSHardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
8th Apr 20227:00 amRNSGrant of share options
6th Apr 20222:59 pmRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSFinal year results for the year ended 31 Dec 2021
9th Mar 20227:00 amRNSDistribution agreement for OrthoPure® XT
2nd Mar 20227:00 amRNSNotice of Results
10th Feb 20223:45 pmRNSAdditional Director Disclosures
27th Jan 20227:00 amRNSFull Year Trading update
23rd Dec 20217:00 amRNSDirector/PDMR Shareholding
21st Dec 20212:06 pmRNSSecond Price Monitoring Extn
21st Dec 20212:01 pmRNSPrice Monitoring Extension
19th Oct 20211:15 pmEQSHardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery
8th Oct 20217:00 amRNSHolding(s) in Company
5th Oct 20214:44 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSHolding(s) in Company
24th Sep 20212:05 pmRNSDirector/PDMR Shareholding
9th Sep 20214:35 pmRNSDirector/PDMR Shareholding
8th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSNotice of Results
1st Sep 20217:00 amRNSLaunch of DermaPure® Meshed and VNEWTM
16th Aug 20217:00 amRNSHolding(s) in Company
14th Jul 20213:15 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Tissue Regenix Group Plc: New capacity now on stream
30th Jun 202111:56 amEQSHardman & Co Research: Tissue Regenix (TRX): Poised for growth
29th Jun 20211:00 pmRNSDirector/PDMR Shareholding
28th Jun 20217:00 amRNSCompletion of phase 1 of new US facility expansion
23rd Jun 20216:08 pmRNSDirector/PDMR Shareholding
10th Jun 20214:17 pmRNSHolding(s) in Company
3rd Jun 20211:37 pmRNSResult of AGM
11th May 20217:00 amRNSDirector/PDMR Shareholding
10th May 202110:00 amRNSDirector/PDMR Shareholding
5th May 20217:00 amRNSGrant of share options
29th Apr 20214:11 pmRNSHolding(s) in Company
28th Apr 20217:00 amRNSFinal Results and Notice of AGM
20th Apr 20211:07 pmRNSHolding(s) in Company
20th Apr 202112:10 pmRNSHolding(s) in Company
19th Apr 20217:00 amRNSNotice of Results
13th Apr 20217:00 amRNSHolding(s) in Company
1st Apr 20214:40 pmRNSSecond Price Monitoring Extn
1st Apr 20214:36 pmRNSPrice Monitoring Extension
18th Mar 20217:00 amRNSInitial phase of US facility expansion complete
26th Feb 20217:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.